[go: up one dir, main page]

BRPI0713349A2 - Inibidores de proteína tirosina fosfatase humana e métodos de utilização - Google Patents

Inibidores de proteína tirosina fosfatase humana e métodos de utilização Download PDF

Info

Publication number
BRPI0713349A2
BRPI0713349A2 BRPI0713349-9A BRPI0713349A BRPI0713349A2 BR PI0713349 A2 BRPI0713349 A2 BR PI0713349A2 BR PI0713349 A BRPI0713349 A BR PI0713349A BR PI0713349 A2 BRPI0713349 A2 BR PI0713349A2
Authority
BR
Brazil
Prior art keywords
tyrosine phosphatase
methods
protein inhibitors
inhibitors
phosphatase protein
Prior art date
Application number
BRPI0713349-9A
Other languages
English (en)
Inventor
Lyle Gray Jeffrey
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38704718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713349(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of BRPI0713349A2 publication Critical patent/BRPI0713349A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INIBIDORES DE PROTEÍNA TIROSINA FOSFATASE HUMANA E MÉTODOS DE UTILIZAÇçO A presente divulgação se refere a compostos eficazes como inibidores de proteína tirosina fosfatase beta humana (IHIPTP -<225>) que desta forma regulam a angiogônese. A presente divulgação se refere ainda a composições que compreendam um ou mais inibidores de proteína tirosina fosfatase beta humana (HIPTP - <225>), e a métodos para regular a angiogênese.
BRPI0713349-9A 2006-06-27 2007-06-27 Inibidores de proteína tirosina fosfatase humana e métodos de utilização BRPI0713349A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81682506P 2006-06-27 2006-06-27
US60/816,825 2006-06-27
PCT/US2007/014824 WO2008002571A2 (en) 2006-06-27 2007-06-27 Human protein tyrosine phosphatase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
BRPI0713349A2 true BRPI0713349A2 (pt) 2012-03-06

Family

ID=38704718

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713349-9A BRPI0713349A2 (pt) 2006-06-27 2007-06-27 Inibidores de proteína tirosina fosfatase humana e métodos de utilização

Country Status (23)

Country Link
US (3) US7589212B2 (pt)
EP (3) EP3287455A1 (pt)
JP (1) JP5201740B2 (pt)
KR (1) KR101157844B1 (pt)
CN (1) CN101506204B (pt)
AU (1) AU2007265455B2 (pt)
BR (1) BRPI0713349A2 (pt)
CA (1) CA2656915C (pt)
CO (1) CO6150143A2 (pt)
CY (1) CY1115588T1 (pt)
DK (2) DK2041129T3 (pt)
ES (2) ES2510674T3 (pt)
HK (1) HK1203960A1 (pt)
IL (1) IL196130A (pt)
MX (1) MX2009000290A (pt)
NZ (1) NZ574405A (pt)
PL (2) PL2041129T3 (pt)
PT (2) PT2041129E (pt)
RU (1) RU2430101C2 (pt)
SI (1) SI2041129T1 (pt)
TR (1) TR201802280T4 (pt)
WO (1) WO2008002571A2 (pt)
ZA (1) ZA200900558B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
RU2539917C2 (ru) * 2009-01-12 2015-01-27 Аэрпио Терапьютикс Инк. Способы лечения синдрома сосудистой утечки
AU2014202211B2 (en) * 2009-01-12 2016-06-02 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
AU2016203254B2 (en) * 2009-01-12 2018-09-13 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
PT2451279T (pt) 2009-07-06 2019-06-18 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composições dos mesmos, e uso dos mesmos na prevenção de metástases de células cancerígenas
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
MX2012005275A (es) 2009-11-06 2012-06-19 Aerpio Therapeutics Inc Composiciones y metodos para tratar colitis.
NZ610230A (en) * 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
MX347226B (es) 2011-10-13 2017-04-19 Aerpio Therapeutics Inc Tratamiento de enfermedad ocular.
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
RU2507597C2 (ru) * 2012-05-23 2014-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ фармакологической коррекции ишемии скелетной мышцы никорандилом
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
ES2928162T3 (es) 2013-03-15 2022-11-15 Eyepoint Pharmaceuticals Inc Composiciones, formulaciones y métodos para tratar enfermedades oculares
RU2526466C1 (ru) * 2013-04-04 2014-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук Средство для стимуляции васкуляризации сердечной мышцы при постинфарктном ее ремоделировании в эксперименте
WO2015126860A1 (en) 2014-02-19 2015-08-27 Aerpio Therapeutics, Inc. Process for preparing n-benzyl-3-hydroxy-4-substituted-pyridin-2-(1h)-ones
JP6483148B2 (ja) * 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド ＨＰＴＰ−β阻害剤
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
EP3352856B1 (en) 2015-09-23 2021-08-18 Aerpio Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
EP3487518A4 (en) 2016-07-20 2020-08-12 Aerpio Therapeutics LLC HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS)
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
US10900319B2 (en) 2017-12-14 2021-01-26 Exacta-Frac Energy Services, Inc. Cased bore straddle packer
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
WO2020223209A1 (en) 2019-04-29 2020-11-05 Aerpio Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
GB2589400A (en) 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof
EP4051267A4 (en) 2019-10-29 2023-12-06 EyePoint Pharmaceuticals, Inc. TIE-2 SMALL MOLECULE ACTIVATORS
CN117343052B (zh) * 2023-12-04 2024-02-06 英矽智能科技(上海)有限公司 蛋白酪氨酸磷酸酶抑制剂及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK1225226T3 (da) 1992-03-13 2008-04-14 Biomerieux Bv Peptider og nucleinsyresekvenser beslægtet med Epstein-Barr-virus
EP0642353A1 (en) * 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5688781A (en) 1994-08-19 1997-11-18 Bristol-Myers Squibb Company Method for treating vascular leak syndrome
ES2333425T5 (es) 1995-06-15 2012-08-28 Crucell Holland B.V. Sistemas de empaquetado para adenovirus recombinante humano destinados a terapia génica
JPH106346A (ja) * 1996-06-19 1998-01-13 Takemoto Oil & Fat Co Ltd プラスチック成形型の製造方法及びプラスチック成形型
AR022303A1 (es) * 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
EP1046715A1 (en) 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
AU5062500A (en) 1999-04-26 2000-11-10 Amersham Pharmacia Biotech Ab Primers for identifying typing or classifying nucleic acids
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU5147700A (en) 1999-05-19 2000-12-05 Amgen, Inc. Crystal of a lymphocyte kinase-ligand complex and methods of use
IL148243A0 (en) 1999-08-27 2002-09-12 Sugen Inc Trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and pharmaceutical compositions containing the same
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
BR0114257A (pt) 2000-09-27 2003-07-01 Procter & Gamble Ligandos de receptores de melanocortina
PE20030968A1 (es) * 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
WO2003082263A1 (en) * 2002-03-29 2003-10-09 Ontogen Corporation Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US20040167183A1 (en) 2003-02-20 2004-08-26 The Procter & Gamble Company Phenethylamino sulfamic acids
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
KR20060073626A (ko) * 2003-09-17 2006-06-28 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 고휘도 방전 램프
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
MY150400A (en) 2006-04-07 2014-01-15 Aerpio Therapeutics Inc Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
PT2451279T (pt) 2009-07-06 2019-06-18 Aerpio Therapeutics Inc Derivados de benzosulfonamida, composições dos mesmos, e uso dos mesmos na prevenção de metástases de células cancerígenas

Also Published As

Publication number Publication date
EP2803663A1 (en) 2014-11-19
EP2041129A2 (en) 2009-04-01
AU2007265455A2 (en) 2009-05-21
US20120077853A1 (en) 2012-03-29
TR201802280T4 (tr) 2018-03-21
CN101506204B (zh) 2012-05-30
EP3287455A1 (en) 2018-02-28
HK1129388A1 (en) 2009-11-27
CO6150143A2 (es) 2010-04-20
CA2656915C (en) 2012-08-07
PL2041129T3 (pl) 2014-11-28
IL196130A (en) 2014-04-30
US8188125B2 (en) 2012-05-29
AU2007265455A1 (en) 2008-01-03
PT2041129E (pt) 2014-10-08
WO2008002571A2 (en) 2008-01-03
US20090227639A1 (en) 2009-09-10
CY1115588T1 (el) 2017-01-04
CA2656915A1 (en) 2008-01-03
PL2803663T3 (pl) 2018-05-30
IL196130A0 (en) 2009-09-22
EP2803663B1 (en) 2017-11-29
MX2009000290A (es) 2009-03-16
WO2008002571A3 (en) 2008-02-14
PT2803663T (pt) 2018-02-28
ZA200900558B (en) 2012-04-24
HK1203960A1 (en) 2015-11-06
EP2041129B1 (en) 2014-09-03
US7589212B2 (en) 2009-09-15
KR101157844B1 (ko) 2012-06-22
AU2007265455B2 (en) 2011-11-10
ES2510674T3 (es) 2014-10-21
JP2009542660A (ja) 2009-12-03
ES2660571T3 (es) 2018-03-23
SI2041129T1 (sl) 2014-11-28
KR20090024296A (ko) 2009-03-06
NZ574405A (en) 2012-01-12
WO2008002571B1 (en) 2008-04-17
CN101506204A (zh) 2009-08-12
US20070299116A1 (en) 2007-12-27
RU2430101C2 (ru) 2011-09-27
US8338615B2 (en) 2012-12-25
RU2009102537A (ru) 2010-08-10
DK2803663T3 (en) 2018-03-05
DK2041129T3 (da) 2014-10-13
JP5201740B2 (ja) 2013-06-05

Similar Documents

Publication Publication Date Title
BRPI0713349A2 (pt) Inibidores de proteína tirosina fosfatase humana e métodos de utilização
BRPI0713357A2 (pt) Inibidores de proteína tirosina fosfatase humana e método de utilização.
WO2008002569A3 (en) Human protein tyrosine phosphatase inhibitors and methods of use
BR112012004453A8 (pt) composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
HN2009000784A (es) Dihidropirazolonas sustituidas
NI201000055A (es) 2&#39; - fluoro - 2&#39; - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
BRPI0720270B8 (pt) compostos 4-fenil-6-(2,2,2-triflúor-1-fenil etoxi) pirimidina, composição e forma de dosagem sólida
BRPI0813499B8 (pt) compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
CR10309A (es) &#34;compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1&#34;
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
PE20120250A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano, forma farmaceutica de la misma, procedimiento para su preparacion
CL2011002818A1 (es) Composicion de leche para el crecimiento que comprende microorganismos probioticos; uso de dicha composicion para preparar medicamento util para prevenir o tratar trastornos inflamatorios.
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
HN2008000317A (es) Benzimidazoles sustituidos como inhibidores de cinasa
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
BR112012017564A2 (pt) Formulação antimicrobiana
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
JO3172B1 (ar) تركيبة وطريقة وتحضير الصفراء الصناعية
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
CR20120264A (es) Compuestos
GT200700064A (es) Agonistas de ep2
CL2008003472A1 (es) Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias.
AR074379A1 (es) Inhibidor de triazolotiadiazola de la proteina quinasa c-met

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: WARNER CHILCOTT COMPANY, LLC (PR)

B25A Requested transfer of rights approved

Owner name: AKEBIA THERAPEUTICS INC. (US)

B25A Requested transfer of rights approved

Owner name: AERPIO THERAPEUTICS INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements